Business Context and Reporting Period
This Form 8-K is filed by AcelRx Pharmaceuticals, Inc. (not TalpherA, Inc.) on June 15, 2023. The report addresses a regulatory compliance matter regarding the company's listing status on The Nasdaq Global Market under the symbol ACRX.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a regulatory event and contains no financial performance data.
Material Changes
The material change reported is the resolution of a listing deficiency:
- Prior Status: On April 26, 2023, Nasdaq notified the company of non-compliance with the Minimum Bid Price Requirement (Listing Rule 5450(a)(1)).
- Current Status: On June 15, 2023, Nasdaq confirmed the company has cured the deficiency and regained compliance.
- Outcome: The matter is now closed.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, or outlook. The primary risk addressed was the potential delisting due to low stock price, which has been mitigated by the company's successful cure of the deficiency.
Investor Verification Checklist
- Verify the current trading price of ACRX to ensure continued compliance with Nasdaq Minimum Bid Price rules.
- Confirm the company's name is AcelRx Pharmaceuticals, Inc., as the input metadata incorrectly referenced "TALPHERA, INC."
- Review subsequent filings for any new compliance notices or financial updates, as this 8-K contains no financial data.